Страница 36: ОСТ 91500.11.0002-2002. Болты,шпильки, гайки и шайбы для фланцевых соединений. Технические требования (78015)

ДАТА

Средства для лечения сердечной
недостаточности
Ингибитор АПФ
______________ мг, ____ раз/сут.
______________ мг, ____ раз/сут.
Сердечные гликозиды
__________________ ____ мг, в/в

______________ мг, ____ раз/сут.
Диуретики
__________________ ____ мг, в/в
__________________ ____ мг, в/в
______________ мг, ____ раз/сут.
______________ мг, ____ раз/сут.

Препараты дополнительного
ассортимента:
__________________ ____ мг, в/в
__________________ ____ мг, в/в
__________________ ____ мг, в/в
__________________ ____ мг, в/в

Препараты, назначенные для лече-
ния сопутствующих заболеваний:
__________________ ____ мг, в/в
__________________ ____ мг, в/в
__________________ ____ мг, в/в

Вес пациента, кг
Объем жидкости, мл:
Выпито
Выделено

Параметры

Дата

Пульс, ударов в минуту:
утро
вечер

АД, мм рт. ст.:
утро
вечер

Объем жидкости в мл:
- выпитой
- выделенной

Стул

+/-

+/-

+/-

+/-

+/-

+/-

+/-

+/-

+/-

+/-

N

Автор(ы)

Название публикации

Выходные
данные

1

Беленков Ю.Н.

Определение качества жизни
у больных с хронической
недостаточностью
кровообращения

Кардиология,
1993;
2: 80 - 85

2

Беленков Ю.Н.,
Мареев В.Ю.,
Агеев Ф.Т.

Медикаментозные пути
улучшения прогноза больных
хронической сердечной
недостаточностью

М., 1997

3

Беленков Ю.Н,
Мареев В.Ю.

Как мы диагностируем и
лечим сердечную
недостаточность в реальной
клинической практике в
начале XXI века

Consilium
medicum, 2001;
2: 65 - 72

4

Белоусов Ю.Б.,
Упницкий А.А.

Особенности фармакокинетики
лекарственных средств при
хронической сердечной
недостаточности

Сердечная не-
достаточность,
2000;
4: 152 - 162

5

Воробьев П.А.
(ред.)

Экономическая оценка
эффективности лекарственной
терапии.
Фармакоэкономический анализ

М., 2000

6

Гендлин Г.Е.,
Самсонова Е.В.,
Бухало О.В.,
Сторожаков Г.И.

Методики исследования
качества жизни у больных
хронической недостаточ-
ностью кровообращения

Сердечная не-
достаточность,
2000;
2: 74 - 80

7

Гиляревский С.Р.,
Орлов В.А.,
Сычева Е.Ю.

Фармакоэкономика хроничес-
кой сердечной недостаточ-
ности: клинические аспекты

М., 2001

8

Глезер М.Г.,
Асташкин Е.И.

Современная концепция
постинфарктного ремоделиро-
вания сердца. Подходы к ме-
дикаментозной терапии

Клин,
Геронтология,
2000;
1 - 2: 33 - 43

9

Горохова С.Г.,
Авксентьева В.М.,
Воробьев П.А.

Анализ экономической
эффективности
допплерэхокардиографии,
применяемой для диагностики
сердечной недостаточности

Проблемы
стандартизации
в здравоохра-
нении, 2001;
1: 39 - 47

10

Горохова С.Г.,
Воробьев П.А.,
Авксентьева М.В.

Фармакоэкономическая оценка
применения некоторых
ингибиторов
ангиотензинпревращающего
фермента при хронической
сердечной недостаточности

Проблемы
стандартизации
в здравоохра-
нении, 2000;
4: 36 - 41

11

Мареев В.Ю.

Рекомендации по рациональ-
ному лечению больных с
сердечной недостаточностью

Consilium
medicum, 1999;
3: 104 - 160

12

Международная статистичес-
кая классификация болезней

13

Международное руководство
по сердечной
недостаточности. Под ред.
С.Дж. Болла, Р.В.Ф.
Кемпбелла, Г.С. Френсиса.
Изд. 2-е

14

Моисеев В.С.

Сердечная недостаточность и
достижения генетики

Сердечная не-
достаточность,
2000;
4: 121 - 130

15

Мухина С.А.,
Тарновская И.И.

Практическое руководство к
предмету "Основы
сестринского дела"

М., Родник,
1998

16

Овчинников А.Н.,
Агеев Ф.Т.,
Мареев В.Ю.

Методические аспекты
применения
допплерэхокардиографии в
диагностике диастолической
дисфункции левого желудочка

Сердечная не-
достаточность,
2000;
2: 66 - 70

17

Ольбинская Л.И.,
Литвицкий П.Ф.

Коронарная и миокардиальная
недостаточность

М., 1986

18

Приказ МЗ РФ от 03.08.99
N 303 "О введении в
действие Отраслевого
стандарта "Протоколы
ведения больных. Общие
положения"

Пробл.
стандартизации
в здравоохра-
нении, 1999;
N 3:
с. 64 - 86

19

Сидоренко Б.А.,
Преображенский
Д.В.

Блокаторы АТ1-ангиотензи-
новых рецепторов

М., 2001

20

Сидоренко Б.А.

Ингибиторы ангиотензин-
превращающего фермента

М., 1999

21

Сидоренко Б.А.,
Преображенский
Д.В.

Лечение и профилактика
хронической сердечной
недостаточности

М., 1997

22

Скворцов А.А.,
Мареев В.Ю.

Бета-блокаторы при
хронической сердечной
недостаточности: какой
тип бета-адренергической
блокады предпочесть?

Consilium
medicum, 2001;
2: 79 - 82

23

Терещенко С.Н.,
Демидова И.В.,
Александрия Л.Г.,
Агеев Ф.Т.

Диастолическая дисфункция
левого желудочка и ее роль
в развитии хронической
сердечной недостаточности

Сердечная не-
достаточность,
2000;
2: 61 - 65

24

Упницкий А.А,
Ханина Н.Ю.,
Ерофеева С.Б.,
Белоусов Ю.Б.

Сравнительное
фармакоэкономическое
исследование ирбесартана
(апровеля) и эналаприла у
пациентов с хронической
сердечной недостаточностью

Пробл.
стандартизации
в здравоохра-
нении, 2000;
4: 33 - 35

25

Федеральное руководство для
врачей по использованию
лекарственных средств.
Выпуск II

М., 2001

26

Cochrane Library

27

Adams K.F. Jr.,
Ellis M.L.,
Williamson K.M.
et al.

The ACPR clinical practice
guideline for heart failure
revisited

Ann.
Pharmacother.,
1997; 31:
1197 - 1204

28

Amiodarone vs
Sotalol Study
Group

Multicentre randomized
trial of sotalol vs
amiodarone for chronic
malignant ventricular
tachyarrhythmias

Europ.
Heart J.,
1989;
10: 685 - 694

29

The Antiarrhythmic versus
Implantable
Defifibrillators. A
comparison of
antiarrhythmic-drug therapy
with implantable
defibrillators in patients
resuscitated from
near-fatal ventricular
arrhythmias

New Engl. J.
Med., 1997;
337:
1576 - 1583

30

Atrial
Fibrillation
Investigators

Risk factors for stroke and
efficacy of antithrombotic
therapy in atrial
fibrillation. Analysis of
pooled data from five
randomized controlled
trials

Arch. Intern.
Med., 1994;
154:
1449 - 1457

31

Australia / New
Zeland Heart
Failure Research
Collaborative
Group

Randomised,
placebo-controlled trial od
carvedilol in patients with
congestive heart failure
due to ischemic heart
disease

Lancet, 1997;
349:
375 - 380

32

Bootman J.I.,
Townsend R.J.,
McGhan W.F.
(eds.)

Principles of
Pharmacoeconomics. Second
ed.

Cincinnati:
Harvey Whitney
Boors Company,
1996

33

Braunwald E.

Congestive heart failure: a
half century perspective

Europ. Heart
J., 2001; 22:
825 - 836

34

Bristow M.R.,
Gilbert E.M.,
Abraham W.T.
et al.
for the MOCHA
Investigators

Carvedilol produces dose -
related improvements in
left ventricular function
and survival in subjects
with chronic heart failure

Circulation,
1996; 94:
2807 - 2816

35

Channer K.S.,
McLean K.A.,
Lawson-Matthew
P., Richardson M.

Combination diuretic
treatment in severe heart
failure refractory to
high-dose loop diuretic and
low-dose angiotensin -
converting enzyme inhibitor

Brit. Heart
J., 1994; 71:
146 - 150

36

CIBIS
Investigators
and Committees

A randomized trial of
beta-blockade in heart
failure: the cardiac
insufficiency bisoprolol
study (CIBIS)

Circulation,
1994; 90:
1765 - 1773

37

CIBIS-II
Investigators and
Committees

The cardiac insufficiency
bisoprolol study (CIBIS -
II): a randomized trial

Lancet, 1999;
353: 9 - 13

38

Cleland J.G.F.

Health economic
consequences of the
pharmacological treatment
of heart failure

Europ. Heart
J., 1998; 19:
32 - 34

39

Cleland J.G.F.,
Louis A.,
Witte K.

Pharmacoeconomics in heart
failure: impact of drug and
non-drug based treatment

Europ. Heart
J., 2001; 3,
Suppl. G.:
G25 - G32

40

Coats A. (ed.)

Controversies in the
management of heart failure

Edinburgh,
1997

41

Cohn J.N.

Critical reviiw of heart
failure: the role of left
ventricular remodeling in
the therapeutic response

Clin.
Cardiol.,
1995; 18,
Suppl.
4: 4 - 12

42

Cody R.J.

Myocardial disease and
congestive heart failure

Bethesda, 1995

43

Cohn J.N.

A comparasion of enalapril
with hydralazine -
isosordie dinitrate in
treatment of chronic
congestive heart failure

New Engl. J.
Med., 1991;
325: 303 - 310

44

Cohn J.N.

Critical reviiw of heart
failure: the role of left
ventricular remodeling in
the therapeutic response

Clin.
Cardiol.,
1995; 18,
Suppl.
4: 4 - 12

45

Cohn J.N.,
Tognoni G.,
Glazer R.D. et
al.

Rationale and disign of the
Valsartan in heart failure
trial: a large
multinationale trial to
assess the effects of
valsartan, an
angiotensin-receptor
blocker, on morbidity and
mortality in chronic
congestive heart failure

J. Card.
Fail., 1999;
5: 155 - 160

46

Colucci W.S.,
Packer M.,
Bristow M.R. et
al.

Carvedilol inhibits
clinical progression in
patients with mild symptoms
of heart failure

Circulation,
1996; 94:
2800 - 2806

47

Cowie M.R.,
Mosterd A.,
Wood D.A. et
al.

The epidemiology of heart
failure

Europ. Heart
J., 1997:
18: 208 - 225

48

The CONSENSUS
Trial Study
Group

Effects of enalapril on
mortality in severe
congestive heart failure.
Results of the Cooperative
North Scandinavian
Enalapril Survival Study

New Engl. J.
Med., 1987;
316:
1429 - 1435

49

Delea Т.Е.,
Vera-Lionch M.,
Richner R.E. et
al.

Cost effectiveness of
carvedilol for heart
failure

Amer. J. Card,
1999; 83 (6):
890 - 896

50

The Digitalis
Investigation
Group

The effect of digoxin on
mortality and morbidity
in patients with heart
failure

New Engl. J.
Med., 1997;
336: 525 - 533

51

Dormans T.P.,
Huige R.M.,
Gerlag P.G.

Chronic intermittent
haemofiltration and
hemodialysis in end stage
chronic heart failure with
oedema refractory to high
dose frusemide

Heart, 1996;
75: 349 - 351

52

Eccles M.,
Freemantle N.,
Mason J.

North of England evidence
based guideline development
project: guideline for
angiotensine converting
enzyme inhibitors in
primary care management of
adults with symptomatic
heart failure

Brit. Med. J.,
1998; 316:
1369 - 1375

53

Engelmeier R.S.,
O'Connell J.B.,
Walsh R. et al.

Improvement of symptoms and
exercise tolerance by
metoprolol in patoents with
dilated cardiomyopathy: a
double-blind, randomized,
placebo-controlled trial

Circulation,
1985; 72:
536 - 546

54

Erhardt L.,
MacLean A.,
Ilgenfritz J.
et al.

Fosinopril attenuates
clinical deterioration and
improves exercise tolerance
in patients with heart
failure

Europ. Heart
J., 1995; 16:
1892 - 1899

55

Feenestra J.,
Grobbee D.E.,
Remme W.J.,
Stricker B.H.

Drug-induced heart failure

J. Amer. Coll.
Card., 1999;
33:
1152 - 1162

56

Fox K.F.,
Cowie M.R.,
Wood D.A. et al.

Coronary disease as a cause
of incident heart failure
in the population

Europ. Heart
J., 2001; 22:
228 - 236

57

Giles Т.D.

Benefits of prolonged
angiotensin-converting
enzyme inhibition in
congestive heart failure

Cardiology,
1991; 79:
16 - 21

58

Glick H.,
Cook J.,
Kinosian B.
et al.

Costs and effects of
enalapril therapy in
patients with symptomatic
heart failure: an economic
analysis of the studies of
left ventricular
dysfunction (SOLVD)
treatment trial

J. Card.
Fail., 1995;
1: 371 - 380

59

Gregory D.,
Udelson J.E.,
Konstam M.A.

Economic impact of beta -
blockade in heart failure

Amer. J. Med.,
2001; 110
(suppl. 1):
74 - 80

60

Haque W.A.,
Boehmer J.,
Clemson B.S. et
al.

Hemodinamic effects of
supplemental oxygen
administration in
congestive heart failure

J. Amer. Coll.
Card., 1996;
27: 353 - 357

61

Heart Failure: Evaluation
and Care of Patients with
Left-Ventricular Systolic
Dysfunction. Clinical
Practice Guideline

AHCPR
Publication
No. 94-0612.
June, 1994

62

Hess O.M.

State of art: current
treatment of heart failure

Europ. Heart
J., 2000; 2
(Suppl. A):
A13 - A16

63

Hobbs F.D.R.,
Jones M.I.,
Allan T.F. et al.

European survey of primary
care physician perceptions
on heart failure diagnosis
and management (Euro-HF)

Europ. Heart
J., 2000; 21:
1877 - 1887

64

Kannel W.B.,
Belanger A.J.

Epidemiology of heart
failure

Amer. Heart
J., 1991; 121:
951 - 957

65

Khand A.U.,
Rankin A.C.,
Kaye G.C.,
Clealand J.G.

Systematic review of the
management of the atrial
fibrillation in patients
with heart failure

Europ. Heart
J., 2000; 21:
614 - 632

66

Kleber F.X.

Impact of converting enzyme
inhibition on progression
of chronic heart failure:
results of the Munich Mild
Heart Failure Trial

Brit. Heart
J., 1992; 67:
289 - 296

67

Kleber F.X.

Socioeconomic aspects of
ACE inhibition in the
secondary prevention in
cardiovascular diseases

Amer.
J. Hypertens.,
1994; 7:
112S - 116S

68

Konstam M.A. et
al. (eds)

Heart failure: evaluation
and care of patients with
left-ventricular systolic
dysfunction

Clinical
practice
guidelines.
N 11. Rock-
ville, 1994

69

Lenihan D.J.,
Gerson M.C.,
Hoit B.D.,
Walsh R.A.

Mechanism, diagnosis and
treatment of diastolic
heart failure

Amer. Heart
J., 1995; 130:
153 - 166

70

Levy P.,
Lechat Ph.,
Leizorovicz A.,
Levy E.

A cost-minimization of
heart failure therapy with
bisoprilol in the French
setting: an analysis from
CIBIS trial data

Cardiovascular
Drugs Therapy,
1998; 12:
301 - 305

71

Levy S.,
Breithardt G.,
Campbell R.W.
et al.

Atrial fibrillation:
current knowledge and
recommendation for
management

Euop. Heart
J., 1998; 19:
1294 - 1320

72

Massie B.M.,
Shah N.B.

Evolving trends in the
epidemiologic factors of
heart failure: Relations
for preventive strategies
and comprehensive disease
management

Amer. Heart
J., 1997; 133:
703 - 712

73

The MERIT-HF
Study Group

Metoprolol CR/XL randomized
intervention trial in
congestive heart failure
(MERIT-HF)

Lancet, 1999;
353:
2001 - 2007

74

McMurray J.,
Davie A.

The pharmacoeconomics of
ACE inhibitors in chronic
heart failure

Pharmacoecono-
mics, 1996; 9:
188 - 197

75

McMurray J.J.,
Petrie M.C.,
Murdack D.R.,
Davie A.P.

Clinical epidemiology of
heart failure: public and
private health burden

Europ. Heart
J., 1998; 19
(Suppl. P):
9 - 16

76

Nishimura R.,
Tajik J.

Evaluation of diastolic
filling of left ventricule
in health and disease:
doppler echocardiography is
the clinician's Rosetta
Stone

J.Amer. Coll.
Card., 1997;
30: 8 - 18

77

Opie L.H.

Angiotensin Converting
Enzyme Inhibitors. 3th
edition

New York, 1999

78

Packer M.,
Cohn J.N.
(eds)

Consensus recommendations
for the management of
chronic heart failure

Amer. J.
Cardiol.,
1999; 83 (2A):
1A - 38A

79

Packer M.,
Gheorghiade M.,
Young J.B.
et al.

Withdeawal of digoxin from
patients with chronic heart
failure treated with
angiotensin-converting
enzyme inhibitors: RADIANCE
study

New Engl. J.
Med., 1993;
329: 1 - 7

80

Packer M.,
Pool-Wilson P.A.,
Armstrong P.W.
et al.

Comparative effects of low
and high doses of the
angiotensin-converting
enzyme inhibitors,
lisinopril, on morbidity
and mortality in chronic
heart failure

Circulation,
1999; 100:
2312 - 2318

81

Pfeffer M.A.,
Braunwald E.,
Moye L.A. et al.

Effects of captopril on
mortality and morbidity in
patients with left
ventricular dysfunction
after myocardial
infarction: Results of the
Survival And Ventricular
Enlargement trial

New Engl. J.
Med., 1992;
327: 669 - 677

82

Philbin E.F.,
Jenkins P.L.

Differences between
patients with heart failure
treated by cardiologists,
internists, family
physicians and other
physicians: analysis of a
large, statewide database

Amer. Heart
J., 2000; 139:
491 - 496

83

Pitt В.,
Segal R.,
Martinez F.A.
et al.

Randomized trial of
losartan versus captopril
in patients over 65 with
heart failure (Evaluation
of Losartan In The Elderly
study, ELITE)

Lancet, 1997;
349: 747 - 752

84

Pitt В.,
Zannad F.,
Remme W.J. et al.

The effect of
spironolactone on morbidity
and mortality in patients
with severe heart failure.
Randomized Aldactone
Evaluation Study
Investigators

New Engl. J.
Med., 1999;
341: 709 - 717

85

Remes J.,
Miettinen H.,
Reunanen A.,
Pyorala K.

Validity of clinical
diagnosis of heart failure
in primary health care

Europ. Heart
J., 1991; 12:
315 - 321

86

Richardson M.,
Cockburn N.,
Cleland J.G.F.

Update of recent clinical
trials in heart failure and
myocardial infarction

Europ. J.
Heart Failure,
1999; 1 (1):
109 - 115

87

Rogers W.J.,
Johnstone D.E.,
Yusuf S.,
Weiner D.H.
et al.

Quality of life among 5025
patients with left
ventricular dysfunction
randomized between placebo
and enalapril: studies of
left ventricular
dysfunction

J. Amer. Coll.
Card., 1994;
23: 393 - 400

88

Ryden L.

A review of evidence of
benefits from ACE
inhibitores in heart
failure compared with AT1 -
receptor blockers and other
therapies

Europ. Heart
J., 1999; 1
(suppl. Q):
Q3 - Q6

89

Sculpher M.J.,
Poole L.,
Cleland J. et al.

Low doses vs high doses of
the angiotensin -
converting enzyme
inhibitor lisinopril in
chronic heart failure: a
cost-effectiveness
analysis based on the
Assessment of Treatment
with Lisinipril And
Survival (ATLAS) study

Europ. J.
Heart Fail.,
2000; 2:
447 - 454

90

Senni M.,
Rodeheffer R.J.,
Tribouilloy C.M.
et al.

Use of echocardiography in
the management of
congestive heart failure in
the community

J. Amer. Coll.
Card., 1999;
33: 164 - 170

91

Setaro J.F.,
Saufer R.,
Remetz M.S.,
Parlmutter R.A.,
Zaret B.L.

Long-term outcome in
patients with congestive
heart failure and intact
systolic left ventricular
performance

Amer. J.
Cardiol.,
1992; 69:
1212 - 1216

92

Singh S.N.,
Fletcher R.D.,
Fisher S.G. et
al.

Amiodaron in patients with
congestive heart failure
and asymptomic ventricular
arrhythmia

New Engl. J.
Med., 1995;
333: 77 - 82

93

SOLVD (Studies of
Left Ventricular
Dysfunction)
Investigators

Effect of enalapril on
survival in patients with
reduced left ventricular
ejection fractions and
congestive heart failure

New Engl. J.
Med., 1991;
325: 293 - 302

94

SOLVD (Studies of
Left Ventricular
Dysfunction)
Investigators

Effect of enalapril on
mortality and the
development of heart
failure in asymptomic
patients with reduced left
ventricular ejection
fractions

New Engl. J.
Med., 1992;
327: 685 - 691

95

Squire I.В.,
MacFayden R.J.,
Reid J.L. et al.

Differing early blood
pressure and renin -
angiotensin system
responses to the first dose
of angiotensin converting
enzyme inhibition in
congestive heart failure

J. Hypertens.,
1995; 27:
657 - 666

96

Strope K.T.,
Forthofer M.M.,
Brater D.C.,
Murrey M.D.

Health care costs of
patients with heart failure
treated with torasemide or
furosemide

Pharmacoecono-
mics, 2000;
17: 429 - 440

97

Task Force on Heart Failure
of the European Society of
Cardiology. Guidelines for
the diagnosis of heart
failure

Europ. Heart
J., 1995; 16:
741 - 751

98

Task Force of Working Group
on Heart Failure of the
European Society of
Cardiology. The treatment
of heart failure

Europ. Heart
J., 1997; 18:
736 - 753

99

Tendera M.

Ageing and heart failure:
the place of ACE inhibitors
in heart failure with
preserved systolic function

Europ. Heart
J., 2000; Vol.
2 (Suppl. 1):
P. 18 - 114

100

Thackray S.,
Witte K.,
Clark A.I.,
Clealand J.G.

Clinical trials update:
OPTIME-CHF, PRAISE-2,
ALL-HAT

Europ. J.
Heart Fail.,
2000; 2:
209 - 212

101

Uretsky B.F.,
Young J.B.,
Shahidi F.E. et
al.

Randomized study assesing
the effect of digoxin
withdrawal in patients with
mild to moderate chronic
congestive heart failure:
results of the PROVED trial

J. Amer. Coll.
Card., 1993;
22: 955 - 962

102

Vandenburg M.J.,
Stephens J.D.,
Resplandy G. et
al.

Digoxin pharmacokinetics
and perindopril in heart
failure patients

J. Clin.
Pharmacol.,
1993; 33:
146 - 149

103

Vasan R.S.,
Larson M.G.,
Benjamin E.J.,
Evans J.C.,
Reiss C.K,
Levy D.

Congestive heart failure in
subjects with normal versus
reduced left ventricular
ejection fraction:
Prevalence and mortality in
a population-based cohort

J. Amer. Coll.
Card., 1999;
33 (7):
1948 - 1955

104

Vitovec J.,
Spinar J.

First-dose hypotension
after angiotensin -
converting enzyme (ACE)
inhibitors in chronic heart
failure: a comparison of
enalapril and perindopril

Europ. J.
Heart Fail.,
2000; 2 (3):
299 - 304

105

Ward R.E.,
Gheorghiade M.,
Young J.B. et al.

Economic outcomes of
withdrawal of digoxin
therapy in adult patients
with stable congestive
heart failure

J. Amer. Coll.
Card., 1995;
26: 93 - 101

106

Weber K.N.,
Villarreal D.

Heart failure: A salt -
sensitive disorder

Columbia
Missuri (USA),
1997

107

Wheeldon M.M.,
MacDonald T.M.,
Flucker C.J.
et al.

Echocardiography in
management of heart failure
in the community

Quart. J.
Med., 1993;
86: 17 - 23

108

Wenger N.K.

Cardiovascular Disease. In:
Cassel C.K., Reisenberg
D.E., Sorensen L.B., Walsh
J.R. Geriatric medicine.
2-d Ed. Springer Verlag

NY-Berlin,
P. 152 - 163

109

Willenheimer R.,
Dahlof В.,
Rydberg E.,
Erhardt L.

AT1-receptor blockers in
hypertension and heart
failure: clinical
experience and future
directions

Europ. Heart
J., 1999;
20 (14):
997 - 1008

110

Williams J.F.,
Bristow M.R.,
Fowler M.B.,
Francis G.S.
et al.

Guidelines for the
evaluation and management
of heart failure. Report of
the American College of
Cardiology / American Heart
Association Task Force on
Practice Guidelines.
Circulation

Circulation,
1995; 92:
2764 - 2784

111

Witte K.,
Thackray S.,
Clark A. et al.

Clinical trials update.
IMPROVEMENT-HF, COPERNICUS,
MUSTIC, ASPECT-II and
APRICOT

Europ. J.
Heart Fail.,
2000; 2:
455 - 461

112

Xie G.Y.,
Berk M.R.,
Smith M.D.,
DeMaria A.N.

Relation of Doppler
transmitral flow patterns
to functional status in
congestive heart failure

Amer. Heart
J., 1996; 131:
766 - 771